Evidence map›Paper›PMID 22451120›Full record

SynthesisDigestive diseases and sciences2012

Sorafenib for treatment of hepatocellular carcinoma: a systematic review.

Bingru Xie, David H Wang, Stuart Jon Spechler

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Bingru XieDepartment of Medicine, VA North Texas Healthcare System, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. Bingru.Xie@va.gov
David H Wang
Stuart Jon Spechler
Southwestern Medical Center · USThe University of Texas Southwestern Medical Center · USVA North Texas Health Care System · US

Funding

Role of Acid in the Development of Barrett's EsophagusR01DK063621 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2002 to 2015
$3.4M
Basic and Clinical Studies on the Role of Bile Acids in Barrett's EsophagusR01CA134571 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2009 to 2013
$1.3M
Clinical Studies on Bile Acids in Barrett's EsophagusI01CX000116 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2009 to 2012
–
CSRD VA I01 CX000116NCI NIH HHS R01 CA134571NCI NIH HHS R01-CA134571NIDDK NIH HHS R01 DK063621
6 · The paper itself

Abstract

backgroundSorafenib, a drug that inhibits Raf serine/threonine kinases mediating cell proliferation and receptor tyrosine kinases involved in angiogenesis, is approved for treatment of advanced hepatocellular carcinoma.

aimsTo explore the efficacy and safety of sorafenib for treating advanced HCC, and to identify clinical factors that might affect that efficacy and safety.

methodsWe conducted a systematic review using the PRISMA guidelines to identify prospective studies on sorafenib used alone or in combination with systemic and/or loco regional anti-tumor therapy for treating advanced HCC.

resultsWe identified 21 prospective trials of sorafenib treatment alone (7) or combined with other treatment (14). In randomized, placebo-controlled trials, sorafenib prolonged overall survival by 2.3-2.8 months, extended the time to tumor progression by 1.4-2.7 months, and increased disease control by 11-19 %. OS and DCRs were lowest for studies with the highest percentage of hepatitis B patients. Most studies reported major side effects (diarrhea, fatigue, and hand-foot syndrome) in <15 % of patients, with greater incidence in patients with advanced cirrhosis and those treated with sorafenib in combination with 5-FU drugs.

conclusionsTreatment with sorafenib results in statistically significant, but clinically modest, improvements in OS, TTP, and DCR. For patients with hepatitis B, response seems to be poorer than for those with hepatitis C. The frequency of hand-foot syndrome seems to be higher when sorafenib is used in advanced cirrhosis and is combined with 5-FU drugs. It is not clear that sorafenib combined with other treatments is more effective than sorafenib alone.

Indexed as

BenzenesulfonatesCarcinoma, HepatocellularLiver NeoplasmsPyridinesAntineoplastic ProtocolsCell ProliferationChemoembolization, TherapeuticHand-Foot SyndromeHepatitis, Viral, HumanHumansLiverLiver CirrhosisNeovascularization, PathologicNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsBenzenesulfonatesNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsPyridinesraf KinasesReceptor Protein-Tyrosine KinasesSorafenib

Identifiers

PMID22451120
PMCPMC3596114
OpenAlexW2070996506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.